Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 6/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | HTR2C | P28335 | 2/20 | 0.58 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21326157 | 0.86 | HTR7 (0.60) | HTR7CYP3A4CYP2D6CYP2C19HTR2A | |
| SCHEMBL29375692 | 0.80 | HTR7 (0.60) | HTR7CYP3A4CYP2D6CYP2C19HTR2A | |
| SCHEMBL7490193 | 0.77 | HTR7 (0.72) | HTR7CYP3A4CYP2D6CYP2C19HTR2A | |
| SCHEMBL8907317 | 0.76 | HTR7 (0.44) | HTR7CYP3A4CYP2D6CYP2C19HTR2A | |
| Tetrahydroharman SCHEMBL29630308 | 0.75 | HTR7 (0.65) | HTR7CYP3A4CYP2D6CYP2C19MAPKAPK2 | |
| Tetrahydroharman SCHEMBL21012020 | 0.75 | HTR7 (0.65) | HTR7CYP3A4CYP2D6CYP2C19MAPKAPK2 | |
| Tetrahydroharman SCHEMBL7018798 | 0.75 | HTR7 (0.65) | HTR7CYP3A4CYP2D6CYP2C19MAPKAPK2 | |
| Tetrahydroharman SCHEMBL29630296 | 0.75 | HTR7 (0.65) | HTR7CYP3A4CYP2D6CYP2C19MAPKAPK2 | |
| SCHEMBL10814283 | 0.75 | HTR7 (0.53) | HTR7CYP3A4CYP2D6CYP2C19HTR2A | |
| SCHEMBL8905846 | 0.74 | HTR7 (0.42) | HTR7CYP3A4CYP2D6CYP2C19HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3600451-B1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2024-12-12 | — | — | US | disclosed |
| US-20240307359-A1 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MINERVA BIOTECHNOLOGIES CORP (US) | 2024-09-19 | — | — | US | disclosed |
| US-11931347-B2 | Method of screening for agents for differentiating stem cells | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MINERVA BIOTECHNOLOGIES CORPORATION | 2021-09-30 | — | — | US | disclosed |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MINERVA BIOTECHNOLOGIES CORPORATION | 2021-09-30 | — | — | US | disclosed |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2021-03-25 | — | — | US | disclosed |
| EP-3600451-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | Minerva Biotechnologies Corporation (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183654-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2018-10-04 | — | — | WO | disclosed |
| US-20180263964-A1 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2018-09-20 | — | — | US | disclosed |
| EP-3352566-A2 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | Minerva Biotechnologies Corporation (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017053886-A2 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017053886-A2 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263964-A1 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MCL1, CRABP2, MYADM | HTR7 3278/4885CYP3A4 4405/4885CYP2D6 4384/4885 |
| US-11931347-B2 | Method of screening for agents for differentiating stem cells | MCL1, CRABP2, MYADM | HTR7 3278/4885CYP3A4 4405/4885CYP2D6 4384/4885 |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MCL1, CD44, EPCAM | HTR7 3547/4885CYP3A4 4476/4885CYP2D6 4379/4885 |
| US-20240307359-A1 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | MCL1, CRABP2, MYADM | HTR7 3278/4885CYP3A4 4405/4885CYP2D6 4384/4885 |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MCL1, CD44, CRABP2 | HTR7 3584/4885CYP3A4 4808/4885CYP2D6 4801/4885 |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | HTR7 3584/4885CYP3A4 4808/4885CYP2D6 4801/4885 |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MCL1, POU2F1, NES | HTR7 2402/4885CYP3A4 3258/4885CYP2D6 3225/4885 |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | HTR7 3584/4885CYP3A4 4808/4885CYP2D6 4801/4885 |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | HTR7 3584/4885CYP3A4 4808/4885CYP2D6 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.